We’re launching LV Apex Suite today, our second Apex Suite after AAV. Each new modality adds data on what’s shared, what’s different, and how to engineer production systems in an integrated way. That’s tied to a core view at @64xbio:
Cell lines, reagents, and process aren't separate levers, they're interdependent parts of a single production system. If we want better productivity, quality, and scalability, we need to understand and engineer that system more holistically.
That’s what we’re building toward with CellMap: data-rich experimental maps of production biology that we can learn from computationally, to guide the design of better cell lines and reagents. Biologics are next, and existing suites will keep expanding with additional tools.
With this, we’re also growing our commercial and ops teams. If you’re excited about building next gen biomanufacturing tools, DM me.
Incredibly proud of the team today for all the work behind this launch. Much more to come.
Cell lines, reagents, and process aren't separate levers, they're interdependent parts of a single production system. If we want better productivity, quality, and scalability, we need to understand and engineer that system more holistically.
That’s what we’re building toward with CellMap: data-rich experimental maps of production biology that we can learn from computationally, to guide the design of better cell lines and reagents. Biologics are next, and existing suites will keep expanding with additional tools.
With this, we’re also growing our commercial and ops teams. If you’re excited about building next gen biomanufacturing tools, DM me.
Incredibly proud of the team today for all the work behind this launch. Much more to come.
New product launch: Today we’re launching LV Apex Suite, a new product suite for lentiviral vector production.View quoted post on X
This marks 64x Bio’s expansion from AAV into LV — and another step in translating our CellMap-driven VectorSelect platform across new modalities.
LV Apex Suite begins with a high yield engineered HEK293T suspension cell line for transient LV production, with stable systems and additional production-enabling technologies in development.
More broadly, this launch reflects where 64x Bio is headed: expanding CellMap as a data foundation for production biology, and learning from those data computationally to iteratively guide development of better cell lines, reagents, and production systems for viral vectors — and soon, biologics.
To learn more about LV Apex Suite, read our press release below and visit 64xbio.com/lvapexsuite.
Press release: 64xbio.com/articles/64x-b…